TASLY Pharmaceuticals Seeks Final US Approval for T89 Drug

TASLY Pharmaceuticals Seeks Final US Approval for T89 Drug

TASLY Pharmaceuticals Seeks Final US Approval for T89 Drug

TASLY Pharmaceuticals seeks final US approval for T89 drug Tests show it can reduce chronic stable angina.

Tasly Pharmaceuticals Inc, is nearing the end of what has been a long road of testing to get approval from the US Food and Drug Administration (FDA) for its T89 drug, a multiple components
traditional Chinese medicine (TCM).

Also known as Dantonic, the drug has been shown to have few adverse side effects and to effectively reduce the frequency of chronic stable angina — a form of chest pain that most often occurs with activity or emotional stress and causes the heart to need more oxygen. Read the full publication "TASLY PHARMACEUTICALS Seeks Final US Approval for T89 Drug" by China Daily.

"T89 can be a reference experience for the
commercialization of innovative Chinese
Medicine (iCM), ultimately more iCM will
be gradually accepted globally to serve the
purpose of filling the therapeutically gaps
and lead to new treatments for patients.”

Henry Sun
President and CEO of Tasly Pharmaceuticals

About HCPnow

HCPNow is providing comprehensive information, a vital believable and trustworthy resource on integrated medicine with a focus on Innovative Chinese medicine (ICM), disease prevention, and treatment.

Learn more
Bitnami